November 4, 2011
Astellas Pharma announced on November 4 that an interim analysis of data from the AFFIRM trial, a PIII clinical trial of the oral androgen receptor signaling inhibitor MDV3100 being conducted in men with prostate cancer in Europe and the US,...read more